New

Create, analyze, optimize your ETF portfolio. Start now →

FBT
US Health Care
Passive
NYSE listed

First Trust NYSE Arca Biotechnology Index Fund ETF

This ETF provides exposure to Equally Weighted US Biotechnology Equities

FBT performance and flow charts

Last update 9/14/2026 at 1:30 PM
Live
Closed
Last price
$264.26
+$2.41 (+0.92%) Yesterday

Performance

-2.00.02.04.06.0%Aug 10Aug 17Aug 24Aug 31Sep 8

Flows

0 M2 M4 M6 M8 M10 M12 M14 M
1 day price range
$261.85
$265.06
52 week price range
$174.16
$274.06
1W perf
-4.14%
YTD perf
+27.43%
YTD flows
+$964M
AuM
$2.86B
E/R
0.54%
TTM yield
-
Find out how industry players manage ETF portfolios.  Discover our library of Model portfolios

Historic performance and flows

Data as of September 10, 2026
1M3MYTD1Y3Y5Y
Perf.+1.52%+17.71%+27.43%+50.50%+73.13%+53.66%
Flows+$13M-$159M+$964M+$1.04B+$626M+$283M
Data as of September 10, 2026

Get all the metrics on this page, and more, through a reliable ETF data feed

Daily, global ETF data for advanced analysis or integration into apps (API), from our partner Trackinsight.

Characteristics

The First Trust NYSE Arca Biotechnology Index Fund ETF is built to track the NYSE Arca Biotechnology Total Return Index - USD. This ETF provides physical exposure - by owning its shares you earn the return of the securities composing the index (as the ETF holds them directly). This share class generates a stream of income by distributing dividends.

Management strategyPassive
StrategyLong Only
ProviderFirst Trust
N° of holdings30
Replication methodDirect (Physical)
Asset classEquity
Dividend policyDistributing
Trailing 12m distribution yield
Join for free
Inception dateJune 19, 2006
ESGNo
TrackinsightTrackinsight

More data and info about FBT on Trackinsight

Exposure

Data as of July 31, 2026

Diversification

55.87%

Total weight of top 15 holdings out of 30

Top 15 Holdings

Halozyme Therapeutics, Inc.
4.31%
Corcept Therapeutics, Inc.
4.08%
Repligen Corp.
3.87%
Regeneron Pharmaceuticals, Inc.
3.85%
BeOne Medicines Ltd.
3.83%
BioNTech SE
3.75%
Natera, Inc.
3.73%
Amgen, Inc.
3.7%
argenx SE
3.66%
NeoGenomics, Inc.
3.63%
Genmab A/S
3.57%
BioMarin Pharmaceutical, Inc.
3.55%
Illumina, Inc.
3.47%
Vertex Pharmaceuticals, Inc.
3.45%
Gilead Sciences, Inc.
3.42%

Sectors

Healthcare
99.86%
Other
0.14%

Countries

USA
82.19%
Other
17.81%

Trading data

Last sale
9/14/2026 at 1:30 PM
$264.26
Previous close
$261.85
Consolidated volume
09/11/2026
Join for free
Average volume
30 days
Join for free
Average discount or premium
30 days
Join for free
Average Bid/Ask spread
30 days
Join for free

Volatility and drawdown

3M1Y3Y5Y
Volatility+22.30%+22.00%+21.10%+22.21%
Max drawdown
-4.37%-14.27%-19.92%-29.49%
Max drawdown duration
30d126d237d1138d
Time to recover
16d63d176d875d

Replication quality

Data as of August 31, 2026
1-year trailing difference

Create an account to view replication metrics

Join for free
Tracking error
Join for free
Tracking difference
Join for free
1 year cumulative return difference
Best
Join for free
Worst
Join for free
daily return difference
Average
Join for free
Worst
Join for free
Advertisement
Frequently asked questions about FBT

What type of ETF is FBT?

FBT is a Passive ETF that provides exposure to Equity assets. It is managed by First Trust.

What index does FBT track?

FBT tracks the NYSE Arca Biotechnology Total Return Index - USD, aiming to replicate its performance through full replication.

What does FBT invest in?

This ETF provides exposure to Equally Weighted US Biotechnology Equities. It is part of the segment: US Health Care.

What is the expense ratio of FBT?

The total expense ratio (TER) of FBT is 0.54%, representing the annual fee charged by the fund manager.

When was FBT launched?

FBT was launched on June 19, 2006, marking its entry into the ETF market.

Who is the issuer of FBT?

FBT is issued by First Trust.

What is the AUM of FBT?

As of September 10, 2026, FBT manages $2.86 B, reflecting the total assets held in the fund.

How has FBT performed recently?

As of September 10, 2026, FBT delivered a return of 1.52% over the past month (1M performance), 17.71% over the past three months (3M), and 27.43% year-to-date (YTD).

What are the recent fund flows for FBT?

As of September 10, 2026, FBT has seen net flows of +$13M in the past month (1M flow) and +$964M year-to-date (YTD).

How many holdings are in FBT

As of July 31, 2026, FBT holds 30 securities in its portfolio. This level of diversification can influence the fund’s risk profile and exposure to individual assets.

How diversified is FBT?

As of July 31, 2026, FBT holds 30 securities, with 55.87% of its assets concentrated in its top 15 holdings.

What are the top holdings of FBT?

As of July 31, 2026, FBT holds a portfolio of 30 underlyings, with its largest positions including Halozyme Therapeutics, Inc., Corcept Therapeutics, Inc. and Repligen Corp.. These top holdings play a significant role in shaping the fund’s performance and exposure.

What countries or regions does FBT invest in?

As of July 31, 2026, FBT has its largest geographic exposures in USA.

What sectors or themes does FBT focus on?

As of July 31, 2026, FBT is primarily exposed to Healthcare.

The ETF Institute® is now affiliated with ETF Central

The CETF certification is the only FINRA listed professional designation focused on ETFs.

ETF Institute
Advertisement
Advertisement
ETF U
Become a better investor with NYSE: The Home of ETFs
Visit the ETF U homepage
ETF Guides
Advertisement

Recent educational content

Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs September 8, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · September 9, 2026
Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs August 31, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · September 1, 2026
Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs August 24, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · August 24, 2026
What's the Fund | Ocean Park Diversified Income ETF (DUKZ)

What’sTheFund

What's the Fund | Ocean Park Diversified Income ETF (DUKZ)

James St Aubin, Chief Investment Officer at Ocean Park Asset Management, discuss the DUKZ ETF, exposing investors to the whole spectrum of asset classes in the fixed income markets, through their rules-based process.

NYSE logo
By NYSE · August 18, 2026

Browse all educational columns

ETF INVESTOR RESOURCES

Expert-Built ETF Portfolios, All in One Place

Don’t start from scratch. Discover ready-made ETF portfolios built by professionals to match different goals, timelines, and market views. Use them as inspiration or as a starting point for your own allocation.

Portfolio Builder